These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 20937812)

  • 1. Resistance profiles of novel electrostatically constrained HIV-1 fusion inhibitors.
    Shimura K; Nameki D; Kajiwara K; Watanabe K; Sakagami Y; Oishi S; Fujii N; Matsuoka M; Sarafianos SG; Kodama EN
    J Biol Chem; 2010 Dec; 285(50):39471-80. PubMed ID: 20937812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide.
    Nishikawa H; Nakamura S; Kodama E; Ito S; Kajiwara K; Izumi K; Sakagami Y; Oishi S; Ohkubo T; Kobayashi Y; Otaka A; Fujii N; Matsuoka M
    Int J Biochem Cell Biol; 2009 Apr; 41(4):891-9. PubMed ID: 18834950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide.
    Naito T; Izumi K; Kodama E; Sakagami Y; Kajiwara K; Nishikawa H; Watanabe K; Sarafianos SG; Oishi S; Fujii N; Matsuoka M
    Antimicrob Agents Chemother; 2009 Mar; 53(3):1013-8. PubMed ID: 19114674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.
    Izumi K; Kodama E; Shimura K; Sakagami Y; Watanabe K; Ito S; Watabe T; Terakawa Y; Nishikawa H; Sarafianos SG; Kitaura K; Oishi S; Fujii N; Matsuoka M
    J Biol Chem; 2009 Feb; 284(8):4914-20. PubMed ID: 19073606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of HIV-1 Resistance to an Electronically Constrained α-Helical Peptide Membrane Fusion Inhibitor.
    Wu X; Liu Z; Ding X; Yu D; Wei H; Qin B; Zhu Y; Chong H; Cui S; He Y
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29321334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor.
    Yu D; Ding X; Liu Z; Wu X; Zhu Y; Wei H; Chong H; Cui S; He Y
    J Biol Chem; 2018 Aug; 293(33):12703-12718. PubMed ID: 29929981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.
    Nameki D; Kodama E; Ikeuchi M; Mabuchi N; Otaka A; Tamamura H; Ohno M; Fujii N; Matsuoka M
    J Virol; 2005 Jan; 79(2):764-70. PubMed ID: 15613304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design.
    Izumi K; Kawaji K; Miyamoto F; Shimane K; Shimura K; Sakagami Y; Hattori T; Watanabe K; Oishi S; Fujii N; Matsuoka M; Kaku M; Sarafianos SG; Kodama EN
    Int J Biochem Cell Biol; 2013 Apr; 45(4):908-15. PubMed ID: 23357451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced antibody-mediated neutralization of HIV-1 variants that are resistant to fusion inhibitors.
    Alam M; Kuwata T; Shimura K; Yokoyama M; Ramirez Valdez KP; Tanaka K; Maruta Y; Oishi S; Fujii N; Sato H; Matsuoka M; Matsushita S
    Retrovirology; 2016 Sep; 13(1):70. PubMed ID: 27670680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.
    Lu L; Tong P; Yu X; Pan C; Zou P; Chen YH; Jiang S
    Biochim Biophys Acta; 2012 Dec; 1818(12):2950-7. PubMed ID: 22867851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 resistance mechanism to an electrostatically constrained peptide fusion inhibitor that is active against T-20-resistant strains.
    Shimane K; Kawaji K; Miyamoto F; Oishi S; Watanabe K; Sakagami Y; Fujii N; Shimura K; Matsuoka M; Kaku M; Sarafianos SG; Kodama EN
    Antimicrob Agents Chemother; 2013 Aug; 57(8):4035-8. PubMed ID: 23689710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Artificial peptides conjugated with cholesterol and pocket-specific small molecules potently inhibit infection by laboratory-adapted and primary HIV-1 isolates and enfuvirtide-resistant HIV-1 strains.
    Wang C; Shi W; Cai L; Lu L; Yu F; Wang Q; Jiang X; Xu X; Wang K; Xu L; Jiang S; Liu K
    J Antimicrob Chemother; 2014 Jun; 69(6):1537-45. PubMed ID: 24500189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two M-T hook residues greatly improve the antiviral activity and resistance profile of the HIV-1 fusion inhibitor SC29EK.
    Chong H; Qiu Z; Sun J; Qiao Y; Li X; He Y
    Retrovirology; 2014 May; 11():40. PubMed ID: 24884671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance.
    Chong H; Yao X; Qiu Z; Sun J; Qiao Y; Zhang M; Wang M; Cui S; He Y
    J Antimicrob Chemother; 2014 Oct; 69(10):2759-69. PubMed ID: 24908047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.
    Su Y; Chong H; Qiu Z; Xiong S; He Y
    J Virol; 2015 Jun; 89(11):5801-11. PubMed ID: 25787278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.
    Su Y; Chong H; Xiong S; Qiao Y; Qiu Z; He Y
    J Virol; 2015 Dec; 89(24):12467-79. PubMed ID: 26446597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
    Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors.
    He Y; Cheng J; Li J; Qi Z; Lu H; Dong M; Jiang S; Dai Q
    J Virol; 2008 Jul; 82(13):6349-58. PubMed ID: 18417584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of a highly potent HIV-1 fusion inhibitor targeting the gp41 pocket.
    Chong H; Qiu Z; Su Y; Yang L; He Y
    AIDS; 2015 Jan; 29(1):13-21. PubMed ID: 25562490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.